BioSig Technologies (OTC: BSGM) is a medical device company preparing to commercialize its PURE EP System, a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to provide high-fidelity cardiac signal recordings and enhanced data. The company has achieved proof-of-concept and has performed preclinical studies at the Mayo Clinic in Minnesota. BioSig is collaborating with several of the nation’s most prestigious cardiac arrhythmia centers to develop, refine and, ultimately, commercialize the PURE EP System. For more information, visit the company’s website at www.biosigtech.com